Dr. Grothey on Dosing Strategies With Regorafenib in CRC


In Partnership With:

Axel Grothey, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Axel Grothey, MD, medical oncologist and director of Gastrointestinal Cancer Research at West Cancer Center and Research Institute, discusses dosing strategies with regorafenib (Stivarga) in colorectal cancer (CRC).

The dosing regimen of 160 mg of oral regorafenib given daily in a 3-weeks-on/1-week-off schedule was approved by the FDA in 2012, says Grothey. However, toxicity remains a concern with this strategy, Grothey explains. Because the main toxicities associated with regorafenib tend to appear within the first few weeks of treatment, the longer a patient can remain on treatment, the more tolerable the agent may become. As such, starting patients on 80 mg of regorafenib and dose escalating up to 160 mg may allow patients to tolerate regorafenib more easily, Grothey says.

Additionally, findings from the phase 2 ReDOS trial, demonstrated that this dose-escalation approach might be more effective than starting patients on 160 mg of regorafenib, says Grothey. However, many patients cannot tolerate regorafenib above 120 mg, Grothey adds. Although trying to maximize dosing to 160 mg is warranted, regorafenib is a cytostatic agent that provides additional benefit the longer a patient is treated, Grothey explains. Therefore, if a patient can sustain 120 mg of regorafenib for a prolonged period of time, maximizing the dose to 160 mg may not be necessary, concludes Grothey.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center